NexgenRx Inc.
NEGXF
$0.20
$0.00351.78%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.67% | 17.26% | 24.43% | 3.55% | 3.58% |
| Total Other Revenue | -2.69% | 13.67% | 26.93% | 70.58% | 110.94% |
| Total Revenue | 20.64% | 17.13% | 24.52% | 5.49% | 5.89% |
| Cost of Revenue | 32.80% | 18.13% | 24.94% | 17.83% | 11.00% |
| Gross Profit | 17.27% | 16.86% | 24.41% | 2.28% | 4.55% |
| SG&A Expenses | 8.10% | 17.01% | 18.72% | 8.21% | 9.51% |
| Depreciation & Amortization | -5.41% | -5.99% | -3.19% | -5.79% | -3.73% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.03% | 14.99% | 17.86% | 8.78% | 8.45% |
| Operating Income | 246.08% | 880.95% | 126.13% | -94.85% | -295.31% |
| Income Before Tax | 181.75% | 128.21% | 155.42% | -108.70% | -69.25% |
| Income Tax Expenses | -5.66% | 1.76% | -0.59% | -58.40% | 9.14% |
| Earnings from Continuing Operations | 212.21% | 464.06% | 137.27% | -5.71% | -96.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 212.21% | 464.06% | 137.27% | -5.71% | -96.97% |
| EBIT | 246.08% | 880.95% | 126.13% | -94.85% | -295.31% |
| EBITDA | 124.57% | 15.77% | 44.25% | 8.41% | -31.65% |
| EPS Basic | 207.14% | 400.00% | 140.00% | -5.26% | -100.00% |
| Normalized Basic EPS | 180.00% | 150.00% | 163.64% | -72.73% | -150.00% |
| EPS Diluted | 200.00% | 400.00% | 125.00% | 0.00% | -87.50% |
| Normalized Diluted EPS | 188.89% | 150.00% | 154.55% | -72.73% | -125.00% |
| Average Basic Shares Outstanding | 0.78% | 0.83% | 0.83% | 0.28% | 0.28% |
| Average Diluted Shares Outstanding | 1.13% | 1.17% | -3.77% | 0.28% | 0.84% |
| Dividend Per Share | -- | 0.00% | -- | -- | -100.00% |
| Payout Ratio | 1.88% | 1.25% | -0.58% | -10.97% | 0.96% |
